Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 69

Results For "LA"

8481 News Found

Surendralal Karsanbhai elected to Merck Board of Directors
People | November 25, 2024

Surendralal Karsanbhai elected to Merck Board of Directors

With the addition of Karsanbhai, the Merck board will consist of 13 members


Sourav Ganguly launches Beurer India's GL 22 Blood Glucose Monitor
Medical Device | November 25, 2024

Sourav Ganguly launches Beurer India's GL 22 Blood Glucose Monitor

The GL 22 Blood Glucose Monitor combines German precision with advanced technology designed to meet local needs


Azenta obtains regulatory approval for clinical long-read whole genome sequencing test
Biotech | November 22, 2024

Azenta obtains regulatory approval for clinical long-read whole genome sequencing test

Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory


Siegfried opens global R&D Center for Drug Substances in Switzerland
News | November 21, 2024

Siegfried opens global R&D Center for Drug Substances in Switzerland

The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth


Briefs: Jagsonpal Pharmaceuticals, Dr. Reddy’s Laboratories and Akums Drugs and Pharmaceuticals
News | November 20, 2024

Briefs: Jagsonpal Pharmaceuticals, Dr. Reddy’s Laboratories and Akums Drugs and Pharmaceuticals

Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities


Lupin launches Bumetanide Injection USP in US
News | November 20, 2024

Lupin launches Bumetanide Injection USP in US

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US


Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma
Clinical Trials | November 19, 2024

Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma

Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex


Natco Pharma appoints Madhava Rao Karicherla as Associate VP – Formulation Research & Development
People | November 16, 2024

Natco Pharma appoints Madhava Rao Karicherla as Associate VP – Formulation Research & Development

He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University


Ecovyst launches AlphaCat advanced silicas products for biocatalysis applications
News | November 16, 2024

Ecovyst launches AlphaCat advanced silicas products for biocatalysis applications

Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential